Copenhagen, 2011-11-04 09:03 CET (GLOBE NEWSWIRE) --
Investor News
Copenhagen, 4 November 2011 - Zealand Pharma A/S (NASDAQ OMX: ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, announces that at the 7th Annual Scrip Awards 2011 on 3 November 2011, the Company won the Management Team of the Year award.
Zealand Pharma was among five international biotechnology and pharmaceutical management teams to be shortlisted for the award, and chosen as the winner by a panel of 16 respected industry judges.
The award, sponsored by Talentmark, the executive and specialist recruitment company, was made to Zealand Pharma as a result of the important achievements its management team made from the period of 1 June 2010 to 31 May 2011. During this period, the team has worked effectively on positioning the company’s growth prospects, securing valuable partnerships with global pharmaceutical leaders and through the consistent delivery of communication around Zealand Pharma’s development, using public news flow and the presentation of clinical data at international scientific conferences.
Commenting on the award, David H Solomon, President and Chief Executive Officer of Zealand Pharma, said: “This has been a transformational year for Zealand Pharma following our successful IPO on NASDAQ OMX Copenhagen with important progress in our pipeline and for our business. Together with our partner Sanofi, we have recently entered the regulatory phase for our most mature drug candidate, Lyxumia® in Type-2 diabetes, and our company now holds near-term sustainable revenue opportunities. I am delighted through this award to see our management team receive important public recognition for its valuable achievements and I look forward, together with the rest of the management team and our dedicated employees, to continuing to build upon our success.”
For further information, please contact:
Hanne Leth Hillman, Vice President for IR & Corporate Communication, Tel: +45 5060 3689, hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide based drugs. The company's lead product is Lyxumia® (lixisenatide), a once-daily GLP-1 agonist, discovered by Zealand Pharma and licensed to Sanofi, which has the drug in late-stage Phase III development with an MAA submitted in Europe for the treatment of Type-2 diabetes. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a licence agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy- and radiotherapy-induced diarrhea.
Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs with favorable therapeutic attributes, and all drug candidates in its pipeline have been identified through the company's own drug discovery activities. Zealand Pharma's products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of
